Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit
Matthew D. Hall, James M. Anderson, Annaliesa S. Anderson, David Baker, Jay Bradner, Kyle R. Brimacombe, Elizabeth A. Campbell, Kizzmekia S. Corbett, Kara Carter, Sara Cherry, Lillian Chiang, Tomáš Cihlář, Emmie de Wit, Mark R. Denison, Matthew D. Disney, Courtney V. Fletcher, Stephanie L. Ford‐Scheimer, Matthias Götte, A Grossman, Frederick G. Hayden, Daria J. Hazuda, Charlotte Lanteri, Hilary D. Marston, Andrew D. Mesecar, Stephanie Moore, Jennifer O. Nwankwo, Jules O’Rear, George R. Painter, Kumar Singh Saikatendu, Celia A. Schiffer, Timothy P. Sheahan, Pei‐Yong Shi, Hugh D. C. Smyth, Michael J. Sofia, Marla Weetall, Sandra K. Weller, Richard J. Whitley, Anthony S. Fauci, Christopher P. Austin, Francis S. Collins, Anthony J. Conley, Mindy I. Davis
Abstract
The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 2019 (COVID-19), including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small-molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development.